In contrast to other haematological neoplasms [134,151,152,153], the presence of SRSF2 mutations has been consistently associated with an adverse prognosis in patients with SM [13,97], particularly among AdvSM cases [11,46,68]. The gene discussed is SRSF2; the disease is systemic mastocytosis.